SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that ...
The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men. SAN FRANCISCO — Decipher, a ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
AZoLifeSciences on MSN
Genomic test can accurately identify early recurrence risk in prostate cancer patients
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
Zacks Investment Research on MSN
Is this the right time to add Veracyte stock to your portfolio?
Veracyte VCYT is making solid progress in its Afirma business line. The company’s Decipher franchise continues to be a strong tailwind, with remarkable test volume growth. Sound financial health also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback